)
)
)
Cloverna
CLOVERNA is a next-generation RNA medicine company unlocking the dark genome to develop first-in-class therapeutics for neurodegenerative diseases and cancer.
Our lead program CLV-201 is a mutation-agnostic antisense oligonucleotide (ASO) that directly resolves TDP-43 aggregation, a convergent pathology found in ~97% of ALS cases.
Discovered through our proprietary DIRAC (Direct RNA Activity Capture) platform integrating CRISPR/dCas13 screening with single-cell analytics, CLV-201 demonstrated >70% aggregate reduction and strong neuronal recovery in patient-derived iPSC models.
CLOVERNA is advancing CLV-201 toward IND in Q4 2026 (US) while expanding the DIRAC platform to additional ncRNA-driven diseases.
Address
KurashikiOkayama
Japan
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)